Bteich Yara T, Hosri Jad E, Wehbi Jad A, Daou Lea R
Lebanese University, Faculty of Medical Sciences, Beirut, Lebanon.
Co-first authors.
Ecancermedicalscience. 2022 Sep 20;16:1447. doi: 10.3332/ecancer.2022.1447. eCollection 2022.
This study aims to determine the current state of clinical trials regarding HPV-positive head and neck squamous cell carcinoma (HNSCC). Clinical trials were filtered to fit the study's aim using Clinicaltrials.gov: trials concerning HNSCC specifically those related to HPV done between January 2005 and December 2020 were extracted and information regarding location, duration, phases, patient recruitment, trial status, results, primary outcome, type of intervention and publication status were collected and analysed. As a result, 123 trials were included. North American countries (USA and Canada) conducted more than two-thirds of the trials (72.4%) compared to European countries and the rest of the world. Trials in phase II constituted more than half of those included in this study (53.7%). From the 123 trials included in this study, only 30 had their NCT identification number linked to publications, but less than half (46.7%) of the publications stemmed from trials with results. Drug combination was the most widely studied treatment modality. Despite falling in the middle of the spectrum with respect to the number of trials when compared to other diseases, our research highlights the need for even more trials tackling multiple aspects of HPV-positive HNSCC.
本研究旨在确定关于人乳头瘤病毒（HPV）阳性头颈部鳞状细胞癌（HNSCC）的临床试验现状。利用美国国立医学图书馆临床试验数据库（Clinicaltrials.gov）筛选符合研究目的的临床试验：提取2005年1月至2020年12月期间关于HNSCC特别是与HPV相关的试验，并收集和分析有关地点、持续时间、阶段、患者招募、试验状态、结果、主要结局、干预类型和发表状态的信息。结果，纳入了123项试验。与欧洲国家和世界其他地区相比，北美国家（美国和加拿大）开展的试验占三分之二以上（72.4%）。II期试验占本研究纳入试验的一半以上（53.7%）。在本研究纳入的123项试验中，只有30项试验的NCT识别号与出版物相关联，但不到一半（46.7%）的出版物来自有结果的试验。联合用药是研究最广泛的治疗方式。尽管与其他疾病相比，该疾病的试验数量处于中等水平，但我们的研究强调需要开展更多针对HPV阳性HNSCC多个方面的试验。
